In this article, we will discuss the 5 pharmaceutical stocks to buy according to Timothy Lynch’s Stonepine Capital based on Q2 2021 holdings of the fund. If you want to read our detailed analysis of Timothy Lynch’s history, investment philosophy, and hedge fund preference, go directly to the 10 Pharmaceutical Stocks to Buy According to Timothy Lynch’s Stonepine Capital.
5. Ovid Therapeutics Inc. (NASDAQ:OVID)
Stonepine Capital’s Stake Value: $7.820 million
Percentage of Stonepine Capital’s 13F Portfolio: 4.08%
Number of Hedge Fund Holders: 15
Ovid Therapeutics Inc. (NASDAQ: OVID) focuses on inventing and developing treatments for individuals who suffer from specific rare neurological conditions such as Angelman syndrome, Fragile X syndrome, Tuberous Sclerosis Complex, and Infantile Spasms. The company was incorporated in 2014 and is placed fifth on the list of 10 pharmaceutical stocks to buy according to Timothy Lynch’s Stonepine Capital.
4. Strongbridge Biopharma plc (NASDAQ:SBBP)
Stonepine Capital’s Stake Value: $9.818 million
Percentage of Stonepine Capital’s 13F Portfolio: 5.13%
Number of Hedge Fund Holders: 12
Founded in 1996 and headquartered in Pennsylvania, Strongbridge Biopharma plc (NASDAQ: SBBP) deals with innovative solutions to cure and manage rare neuromuscular and endocrine conditions. It is ranked fourth on the list of 10 pharmaceutical stocks to buy according to Timothy Lynch’s Stonepine Capital. Strongbridge Biopharma plc (NASDAQ: SBBP) has a market capitalization of $135.658 million.
3. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)
Stonepine Capital’s Stake Value: $14.446 million
Percentage of Stonepine Capital’s 13F Portfolio: 7.43%
Number of Hedge Fund Holders: 15
Based on the latest 13F holdings for the second quarter of 2021, Stonepine Capital owns over 2.6 million shares in Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) worth $14.226 million. On August 9, Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) posted the earnings for Q2 2021. The company posted earnings per share of $ -$0.27, beating the market predictions by $0.02. The revenue was announced to be $21.97 million, up 12.48% year over year, which beat market predictions by $160,000.
2. CTI BioPharma Corp. (NASDAQ:CTIC)
Stonepine Capital’s Stake Value: $19.081 million
Percentage of Stonepine Capital’s 13F Portfolio: 9.97%
Number of Hedge Fund Holders: 10
Another notable stock in Timothy Lynch’s portfolio is CTI BioPharma Corp. (NASDAQ: CTIC). The fund holds a $19.081 million stake in the company. Since the previous quarter, Stonepine Capital has increased its stake by 132% in CTI BioPharma Corp. (NASDAQ: CTIC).
1. Amryt Pharma plc (NASDAQ:AMYT)
Stonepine Capital’s Stake Value: $33.937 million
Percentage of Stonepine Capital’s 13F Portfolio: 17.74%
Number of Hedge Fund Holders: 11
Amryt Pharma plc (NASDAQ: AMYT), headquartered in the United Kingdom, is a biopharmaceutical company dedicated to providing treatments to people with rare, debilitating diseases. Since its inception in 2015, the company has commercialized three products.
In Amryt Pharma plc (NASDAQ: AMYT), Stonepine Capital owns over 2.7 million shares. The investment covers 17.74% of the fund’s portfolio. Interestingly, Stonepine Capital has increased its stake in the company by 11% since the previous quarter, which indicates that the company has good prospects.
At the end of the second quarter, there were 11 hedge funds in Insider Monkey’s database that held stakes in Amryt Pharma plc (NASDAQ: AMYT) as compared to 8 hedge funds in the first quarter. Timothy Lynch’s Stonepine Capital owns over 2.79 million shares of Amryt Pharma plc (NASDAQ: AMYT) which amounts to a worth of $33.937 million.
You can also take a peek at the 15 Dividend Stocks People Buy for Early Retirement and 10 Best Tech ETFs to Buy According to Reddit.
